vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

Stock Information for Clearday Inc Ordinary Shares

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Clearday Inc Ordinary Shares

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board
vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting
UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences
vTv Therapeutics to Participate in Upcoming September Investor Conferences
vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund
vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.